Evaluating the Efficacy of ERG Targeted Therapy in vivo for Prostate Tumors
Abstract
The proposal centers on developing the principal investigator (PI) into an independent prostate cancer physician-scientist, using as a vehicle this DoD award with specific research aims to examine the ERG oncoprotein as a target for prostate cancer therapy by using novel transgenic mice. As many as 50% of prostate cancers possess a chromosomal translocation involving the ERG oncogene. I hypothesized that ERG can serve as an effective molecular therapeutic target for prostate tumors using novel prostate tumor mouse models. During this fifth year of support we have not been able to adhere to our Statement of Work for Task#2 or Task#3. We were successful at completing Task#1, but characterization of ERG expression from our prostate mouse model did not demonstrate any detectable prostate specific ERG expression at the protein level. To remedy this issue, we re-started Task #1 two years ago with the new prostate specific TET driver mouse,Hoxb13-rtTA. We have spent this last year examining whether ERG can collaborate with AKT1 with these new mice, Hoxb13-rtTA/tetO-ERG. We had to reinitiate breeding of more mice using a different tetO-ERG founder line and are in the midst of processing samples for analysis. Despite these setbacks, concurrently during this award period and made possible by this DoD award, the PI has made significant strides in promoting his career as an independently funded prostate cancer physician-scientist with national and international recognition.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2016
- Accession Number
- AD1011713
Entities
People
- Phouc T. Tran
Organizations
- Johns Hopkins University